Move from alliance sprawl to ecosystems in life sciences

Life sciences organizations have built their operating models on a growing web of vendors and strategic partners to keep complex work moving across research and development (R&D), quality management, compliance, and operations. Now the limits are showing. Point-to-point alliances keep multiplying, but few are designed to work together as one system. Misaligned partners, duplicated validation, and poorly coordinated systems can slow execution—and delays are expensive. The Tufts Center for the Study of Drug Development estimates that each day a drug launch is delayed, it costs sponsors roughly $500,000 in lost sales (May 2024). Many organizations also cite challenges such as costs outpacing revenue, too many vendors to manage, and limited benefit from artificial intelligence (AI) despite significant investment.

Ecosystems offer a more intentional model. This shift is not about adding more technology or replacing partnerships. It is about reorganizing partners and platforms around shared value streams, backed by the data, governance, and operating models needed to orchestrate the network. In KPMG surveys, 75 percent of senior leaders say partner ecosystems fuel growth, innovation, and agility. 83 percent of senior leaders expect to expand partner networks in the next one to three years.

What ecosystems can help you do:

• Cut bottlenecks by reducing repeated reconciliation, evidence re-creation, and integration revalidation
• Minimize redundant data movement so data can be reused across functions and partners
• Strengthen execution in regulated environments through clearer orchestration across partners and platforms

Download our full paper, From point-to-point alliance sprawl to ecosystems, to explore the model and what it takes to make ecosystems work.